Kala Pharmaceuticals Inc. has filed for an initial public offering, according to a Securities and Exchange Commission filing on Friday. The Waltham, Mass.-based company focuses on the treatment of eye diseases and listed net losses of $17 million in 2015, $33 million last year, and $10 million in the first three months of this year. The company is expected to trade on the Nasdaq under the symbol KALA.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News